Filling up: Thermo Fisher plans $130m Singapore plant

Thermo Fisher says it will add two filling lines in Singapore to support growing demand for sterile injectables.

Dan Stanton, Managing editor

October 19, 2020

1 Min Read
Filling up: Thermo Fisher plans $130m Singapore plant
Image: iStock/dk_photos

Thermo Fisher will add two filling lines in Singapore to support growing demand for sterile injectables.

The $130 million facility will be established with the support of the Singapore Economic Development Board (EDB) and operated by Thermo Fisher.

“Thermo Fisher will be building out and operating a new facility that will serve as a new regional steriles manufacturing site for our customers and, in addition, will provide priority access to the Singapore government during future health emergencies,” a Thermo Fisher company spokesperson told this publication.


Image: iStock/dk_photos

“The site will help meet the growing demand for steriles – both globally and especially in the region and will deliver an important capability to help our customers operate with speed, efficiency, and agility.”

The facility will initially include a high-speed sterile line approved for live virus filling – the first such large scale capability in Singapore – followed by an additional line for standard fill/finish. Furthermore, the plant will have cleanroom capacity, labs, warehousing and offices to support production.

“We are not constructing a brand new production shell, but we will convert an existing building into a steriles operation  that will expand Thermo Fisher’s footprint in Singapore,” the company said.

According to the firm, the facility could manufacture up to 30 million sterile doses per month and employ more than 300 people, once operational in 2022.

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.

Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.

From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like